Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study

• Published in: Japanese journal of clinical oncology 2024-10
• Main Authors: Hara, Shuhei, Urabe, Fumihiko, Tashiro, Kojiro, Goto, Yuma, Iwamoto, Yuya, Ohtsuka, Takashi, Fukuokaya, Wataru, Imai, Yu, Iwatani, Kosuke, Atsuta, Mahito, Mori, Keiichiro, Igarashi, Taro, Aikawa, Koichi, Yanagisawa, Takafumi, Kimura, Shoji, Murakami, Masaya, Tsuzuki, Shunsuke, Yanada, Brendan A, Hata, Kenichi, Furuta, Akira, Yamada, Hiroki, Miki, Jun, Kimura, Takahiro
• Format: Article
• Language: English
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyae146

We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes. This retrospective study included 145 nmCRPC patients who received enzalutamide, apalutamide or darolutamide at the Jikei University Hospital or its affiliated institutions between May 2014 and November 2022. Patients were stratified based on prostate-specific antigen (PSA) doubling time (PSADT) at CRPC diagnosis and PSA levels at ARSI initiation. Oncological outcomes, including progression-free survival (PFS), metastasis-free survival (MFS), cancer-specific survival and overall survival, were assessed using the Kaplan-Meier curve and Cox regression analysis. The median age of the patients was 73 (interquartile range [IQR]: 52-88) years, and the median follow-up duration was 36 (IQR: 2-104) months. The median PSA level at ARSI initiation was 5.4 (IQR: 2.2-48) ng/ml, and 44.8% of patients had a PSADT